Eisai and Biogen launch Leqembi in Austria, Germany

Eisai (ESAIY) and Biogen (BIIB) announced that the anti-amyloid beta monoclonal antibody Leqembi has been launched in Austria on August 25 and will be launched in Germany on September 1. Leqembi received the European Commission approval in April as the first therapy that targets an underlying cause of Alzheimer’s disease. It is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to AD who are apolipoprotein E e4 non-carriers or heterozygotes with confirmed amyloid pathology. Germany and Austria will mark the first launches in the EU. Following the EC approval, Eisai has been collaborating with the regional and local healthcare authorities to implement the mandatory authorization requirements ahead of launch. The required controlled access program is now in place in Austria and Germany, enabling the launch in these first two EU countries.